Drug Profile
LAG 078
Latest Information Update: 29 Oct 2002
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 17 Oct 2002 Discontinued for Hyperlipidaemia in Europe (unspecified route)
- 06 Nov 2001 New profile
- 06 Nov 2001 Investigation in Hyperlipidaemia in Europe (Unknown route)